肝素及硫酸镁对肺心病心衰患者血气及血液黏度的影响  

Effects of heparin combined with magnesium sulfate on blood gas and blood viscosity in patients with pulmonary heart failure

作　　者：邓睿[1] 梁红卫[1] 廖军红[1] 陈俊华[1] 刘海燕[1] 

机构地区：[1]广东省江门市人民医院呼吸内科,广东江门529000

出　　处：《海南医学院学报》2016年第20期2383-2385,共3页Journal of Hainan Medical University

基　　金：江门市科学技术局(20120020037360)~~

摘　　要：目的:观察肝素联合硫酸镁治疗肺心病合并呼吸衰竭患者的血气指标和血液黏度的影响,并观察临床疗效。方法:将我院收治的80例肺心病合并呼吸衰竭患者随机分为观察组(n=40)和对照组(n=40),对照组采用肺心病常规对症治疗,观察组在此基础上给予肝素联合硫酸镁静脉滴注。两组均治疗2个疗程,治疗结束后,比较两组血气指标、血液黏度指标、肺动脉收缩压(PAPs)、SBP、DBP等各项检测指标,统计两组临床疗效。结果:治疗2个疗程后,两组PaO_2及PaCO_2均有所改善,pH值无明显变化,观察组PaO_2显著高于对照组,而PaCO_2则显著低于对照组,差异均具有统计学意义(P<0.01);与治疗前比较,两组血液流变学指标均有不同程度的降低(P<0.05或P<0.01),其中观察组WBV、PV、Hct、EAI与对照组比较,差异有统计学意义(P<0.01);治疗后观察组较对照组PAPs明显降低,差异具有统计学意义(P<0.05);SBP和DBP比较,差异无统计学意义(P>0.05)。结论:肝素联合硫酸镁治疗肺心病合并呼吸衰竭,可以改善患者的血气指标和血液黏度指标,降低肺动脉收缩压,有较高的疗效,具有临床推广价值。Objective：To observe the effects of heparin combined with magnesium sulfate on the blood gas indicators and blood viscosity in patients with pulmonary heart disease merged with respiratory failure.Methods：A total of 80 patients with pulmonary heart disease merged with respiratory failure who were admitted in our hospital were included in the study and randomized into the observation group（n=40）and the control group（n=40）.Patients in control group were given routine symptomatic treatments of pulmonary heart disease.On the above basis,the patients in the observation group were given intravenous drip of heparin and magnesium sulfate.Patients in both groups were treated for 2 weeks.The blood gas indicators,blood viscosity indicators,PAPs,SBP,and DBP in the two groups were compared.The clinical efficacy in the two groups was evaluated.Results：After 2-week treatment,PaO_2 and PaCO_2 in the two groups were improved,pH value was not significantly changed,PaO_2 in the observation group was significantly higher than that in the control group,while PaCO_2 was significantly lower than that in the control group（P〈0.01）.The hemorheology indicators after treatment in the two groups were significantly reduced when compared with before treatment（P〈0.05 or P〈0.01）,among which the comparison of WBV,PV,Hct,and EAI between the two groups was statistically significant（P〈0.01）,and PAPs after treatment in the observation group was significantly reduced when compared with the control group（P〈0.05）.SBP and DBP after treatment in the two groups were not significantly changed（P〉0.05）.Conclusions：Heparin in combined with magnesium sulfate in the treatment of pulmonary heart disease merged with respiratory failure can improve the blood gas indicators and blood viscosity indicators,and reduce SBP of pulmonary artery,with a higher efficacy;therefore,it deserves to be widely recommended in the clinic.

关 键 词：肺心病 呼吸衰竭 肝素 硫酸镁 

分 类 号：R541.5[医药卫生—心血管疾病]